November 26, 2025 — Houston, Texas — Leads & Copy — Moleculin Biotech, Inc. (Nasdaq: MBRX) has announced it has filed an amendment to its amended and restated certificate of incorporation with the Secretary of State of the State of Delaware to effect a 1-for-25 reverse stock split of its common stock, according to a press release issued by the company.
The reverse stock split will take effect at 12:01 a.m. Eastern Time on December 1, 2025. Trading on The Nasdaq Capital Market will commence on December 1, 2025, on a post-split basis, under the existing ticker symbol “MBRX” but with a new CUSIP number 60855D 408.
The company’s common stock outstanding will be reduced from approximately 51.7 million shares to approximately 2.1 million shares as a result. The number of authorized shares of common stock will remain at 500 million shares.
As a result of the reverse stock split, every 25 shares of the company’s common stock issued and outstanding prior to the opening of trading on December 1, 2025, will be consolidated into one issued and outstanding share, with no change in the nominal par value per share of $0.001.
No fractional shares will be issued if a stockholder would become entitled to a fractional share because the number of shares of common stock they hold before the reverse stock split is not evenly divisible by the split ratio. Instead, the stockholder will receive a cash payment.
Moleculin Biotech, Inc. is a Phase 3 clinical stage pharmaceutical company advancing a pipeline of therapeutic candidates addressing hard-to-treat tumors and viruses. The company’s lead program, Annamycin, is a next-generation anthracycline designed to avoid multidrug resistance mechanisms and to lack the cardiotoxicity common with currently prescribed anthracyclines.
Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases. The company has begun the MIRACLE (Moleculin R/R AML AnnAraC Clinical Evaluation) Trial (MB-108), a pivotal, adaptive design Phase 3 trial evaluating Annamycin in combination with cytarabine, together referred to as AnnAraC (the combination of Annamycin and cytarabine, also referred to as “Ara-C”) and, for the treatment of relapsed or refractory acute myeloid leukemia.
Following a successful Phase 1B/2 study (MB-106), with input from the FDA, the company believes it has substantially de-risked the development pathway towards a potential approval for Annamycin for the treatment of AML. This study remains subject to appropriate future filings with potential additional feedback from the FDA and their foreign equivalents.
Additionally, the company is developing WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers. Moleculin also has in its pipeline a portfolio of antimetabolites, including WP1122 for the potential treatment of pathogenic viruses, as well as certain cancer indications.
Jenene Thomas, JTC Team, LLC, (908) 824-0775, MBRX@jtcir.com
Source: Moleculin Biotech, Inc.
